Related Experiment Video
Updated: Jun 9, 2025
Drug Treatment and In Vivo Imaging of Osteoblast-Osteoclast Interactions in a Medaka Fish Osteoporosis Model
Published on: January 1, 2017
Mining and analysis of adverse event signals for alendronate based on the real-world data of FDA adverse event
Ziyi Zhao1, Hongxiang Ji2, Chenghao Zhang1
1Department of Hand and Foot, Microsurgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
Objective:
Our study aims to assess alendronate-related adverse events (AEs) from the US FDA adverse event reporting system database.
Methods:
The AE data associated with alendronate between the first quarter of 2004 and the first quarter of 2024 were selected. Various signal quantification methods, including the ROR, PRR, BCPNN, and EBGM, were applied for analysis.
Results:
In 34,943 reports where alendronate was the primary suspected drug for the AE, 24 affected system organ classes and 1046 significant preferred terms were identified in this study. Several significant AEs beyond drug instructions with strong signals were determined, including low turnover osteopathy, fracture delayed union, fracture nonunion, loss of anatomical alignment after fracture reduction, fracture malunion, periprosthetic fracture, carotid bruit, oral fibroma, traumatic occlusion, and phlebolith. The median time to onset of alendronate-related AEs was 306 days (interquartile range [IQR] 12-1,461 days), and the majority of cases occurred 2 years later (18.80%) and within 30 days (14.49%).
Conclusions:
The current study detected multiple potential new AE signals for alendronate, and more clinical research is required to further validate our results and clarify their associations.
